By

Sanofi Pasteur, the vaccines division of Sanofi , Wednesday announced that the final landmark phase III efficacy study of its dengue vaccine candidate in Latin America successfully achieved its primary...

By

Sanofi Pasteur, the vaccines division of Sanofi announced this week in The Lancet the detailed results of  its first landmark phase III dengue vaccine efficacy study conducted in five countries in Asia....

The mosquito borne viral disease, Dengue fever, causes significant illness and death worldwide, in fact, the World Health Organization (WHO) says over 2.5 billion people – over 40 percent of the world’s...